

**Final - June 20, 2023**

**MEETING OF THE ADVISORY COMMITTEE ON IMMUNIZATION PRACTICES (ACIP)**

Centers for Disease Control and Prevention

Atlanta, Georgia 30329

June 21-23, 2023

**Wednesday, June 21, 2023**

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
<b>8:30</b>	<b>Respiratory Syncytial Virus Vaccines - Adult</b>  Introduction Manufacturer presentation: Pfizer season 2 safety & efficacy; coadministration with influenza vaccine Manufacturer presentation: GSK season 2 safety & efficacy; coadministration with influenza vaccine Updated cost-effectiveness of the Pfizer and GSK vaccines (main CDC model) Comparison of cost effectiveness results of the main CDC model and each manufacturer model (Pfizer & GSK) Updated EtR (incl. GRADE) and clinical considerations for 2 vaccines (Pfizer & GSK)	Dr. Camille Kotton (ACIP, WG Chair) Dr. Alejandra Gurtman (Pfizer)  Dr. Leonard Friedland (GSK)  Dr. David Hutton (University of Michigan)  Dr. Ismael Ortega Sanchez (CDC/NCIRD)  Dr. Michael Melgar (CDC/NCIRD)
<b>11:45</b>	<b>Break</b>	
<b>12:45</b>	<b>Polio Vaccine</b>  Introduction Recommendations for Adult Polio Vaccination	Dr. Oliver Brooks (ACIP, WG Chair) Dr. Sarah Kidd (CDC/NCIRD)
<b>2:15</b>	<b>Break</b>	
<b>2:30</b>	<b>Influenza Vaccines</b>  Introduction WG considerations and proposed recommendations	Dr. H. Keipp Talbot (ACIP, WG Chair) Dr. Lisa Grohskopf (CDC/NCIRD)
<b>4:00</b>	<b>Break</b>	
<b>4:15</b>	<b>Public Comment</b>	
<b>4:35</b>	<b><u>VOTES</u></b>  RSV Adult Vaccines Polio Vaccine Influenza Vaccines <b><u>VFC VOTE</u></b> Influenza Vaccines <b>Adjourn</b>	Dr. Michael Melgar (CDC/NCIRD) Dr. Sarah Kidd (CDC/NCIRD) Dr. Lisa Grohskopf (CDC/NCIRD)  Dr. Jeanne Santoli (CDC/NCIRD)

## Final - June 20, 2023

**Thursday, June 22, 2023**

8:00	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair) Dr. Melinda Wharton (ACIP Executive Secretary, CDC)
8:35	<b>Agency Updates</b> <i>CDC, CMS, FDA, HRSA, IHS, OIDP, NIH</i>	
8:55	<b>Pneumococcal Vaccines</b> Introduction Economic analysis and public health impact of PCV20 use in children Comparison of cost-effectiveness analyses on PCV20 use in children Summary of WG interpretation on EtR and policy options	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Charles Stoecker (Tulane University)  Dr. Ayabina Diepreye (CDC/NCIRD)  Dr. Miwako Kobayashi (CDC/NCIRD)
10:25	<i>Break</i>	
10:40	<b>Dengue Vaccines</b> Introduction Introduction of policy questions for TAK-003 Cost effectiveness analysis and health impacts of routine vaccination with TAK-003 dengue vaccine in Puerto Rico	Dr. Wilbur Chen (ACIP, WG Chair) Dr. Alfonso Hernandez (CDC/NCEZID) Dr. Guido Espana (University of Notre Dame)
	Summary of two economic models for dengue vaccine TAK-003 use in Puerto Rico	Dr. RajReni Kaul (CDC/NCIRD)
	Partial EtR framework for TAK-003	Dr. Joshua Wong (CDC/NCEZID)
11:40	<i>Break</i>	
12:25	<b>Chikungunya Vaccine</b> Introduction Value of chikungunya vaccine to U.S. travelers and providers Chikungunya virus infection among laboratory workers Update on large chikungunya outbreak in Paraguay Workgroup plans and timelines	Dr. Beth Bell (ACIP, WG Chair) Ms. Nicole Lindsey (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID) Dr. Susan Hills (CDC/NCEZID)
1:25	<i>Break</i>	
1:40	<b>Respiratory Syncytial Virus Vaccines - Pediatric/Maternal</b>  Introduction Economic analysis of RSVpreF in pediatric populations EtR Pfizer maternal RSV vaccine Economic analysis of combined use of nirsevimab and maternal RSVpreF vaccine Clinical considerations for RSV maternal vaccine and nirsevimab	Dr. Sarah Long (ACIP, WG Chair) Dr. David Hutton (University of Michigan) Dr. Katherine Fleming-Dutra (CDC/NCIRD) Dr. David Hutton (University of Michigan)  Dr. Jefferson Jones (CDC, NCIRD)
4:40	<i>Break</i>	
4:50	<b>Public Comment</b>	
5:10	<b>VOTES</b> Pneumococcal vaccines <b>VFC VOTE</b> Pneumococcal Vaccines	Dr. Jeanne Santoli (CDC/NCIRD)  Dr. Jeanne Santoli (CDC/NCIRD)
5:30	<b>Adjourn</b>	

## Final - June 20, 2023

### **Friday, June 23, 2023**

<b>8:00</b>	<b>Welcome &amp; Introductions</b>	Dr. Grace Lee (ACIP Chair)
<b>8:10</b>	<b>Mpox Vaccine</b> Introduction Updates From the 2022/2023 U.S. Mpox Outbreak: Epidemiology, Vaccine Safety, and Vaccine Effectiveness	Dr. Pablo Sanchez (ACIP, WG Chair) Dr. Faisal Minhaj (CDC/NCEZID)
	Use of JYNNEOS During Mpox Outbreaks: Clinical guidance	Dr. Agam Rao (CDC/NCEZID)
	Considerations for Long-term Protection Against Mpox	Dr. Agam Rao (CDC/NCEZID)
<b>10:10</b>	<b>Break</b>	
<b>10:20</b>	<b>Meningococcal Vaccines</b> Introduction Cost effectiveness analysis GRADE/EtR Summary and workgroup considerations	Dr. Kathy Poehling (ACIP, WG Chair) Dr. Ismael Ortega-Sanchez (CDC/NCIRD) Dr. Sam Crowe (CDC/NCIRD) Dr. Sam Crowe (CDC/NCIRD)
<b>11:35</b>	<b>Break</b>	
<b>11:45</b>	<b>Vaccine Safety</b> The childhood immunization schedule and safety: Studies in the Vaccine Safety Datalink Preliminary evaluation of aluminum content in childhood vaccines and risk of asthma in a Danish nationwide cohort	Dr. Tom Shimabukuro (CDC/NCEZID) Dr. Matthew Daley (Kaiser Permanente Colorado)  Dr. Anders Hviid (Statens Serum Institut, Copenhagen, Denmark)
<b>12:30</b>	<b>Break</b>	
<b>12:40</b>	<b>COVID-19 Vaccines</b> Introduction Updates to COVID-19 epidemiology and vaccine effectiveness	Dr. Matthew Daley (ACIP WG Chair) Dr. Fiona Havers (CDC/NCIRD), Dr. Romeo Galang (CDC/NCCDPHP), Dr. Ruth Link-Gelles (CDC/NCIRD)
	Infection-induced and hybrid immunity Summary and work group considerations	Dr. Jefferson Jones (CDC/NCIRD) Dr. Megan Wallace (CDC/NCIRD)
<b>2:40</b>	<b>Adjourn</b>	

### ***Acronyms***

CDC	Centers for Disease Control and Prevention
CMS	Centers for Medicare and Medicaid Services
COVID-19	Coronavirus disease 2019
EtR	Evidence to Recommendations Framework
FDA	Food and Drug Administration
GRADE	Grading of Recommendations Assessment, Development and Evaluation
HRSA	Health Resources and Services Administration
IHS	Indian Health Service
NCHHSTP	National Center for HIV, Hepatitis, STD and TB Prevention [of CDC/OID]
NCIRD	National Center for Immunization & Respiratory Diseases [of CDC/OID]
NCEZID	National Center for Emerging and Zoonotic Diseases [of CDC/OID]
NIAID	National Institute of Allergy and Infectious Diseases
OIDP	Office of Infectious Disease and HIV/AIDS Policy
SARS-CoV-2	Severe Acute Respiratory Syndrome Coronavirus 2
WG	Work Group
WHO	World Health Organization
VE	Vaccine Effectiveness